At the risk of dragging things back on topic, I just wanted to say why I think this is a great study, and why I've donated.
I waited nearly twenty years to see classy researchers come into mecfs from other fields, and they don't get much classier than Ian Lipkin: we should encourage him (same goes for Ron Davis). I wish the NIH would fund this study, but they didn't even give enough to cover sample collection, so for now it's down to patients to make this happen.
Good things about the study (in my view)
1. The samples/patients
It's big, with 125 Canadian criteria patients and 125 matched controls. Plus the team have gone to great lengths to recruit a representative sample, by teaming up with clinics from all over the US (using mecfs specialist clinics) and asking clinics to recruit a broad range of patients, not just particular types.
Then, they are making sure that each sample comes from a three-month window to account for natural seasonal variation in bacteria, viruses and fungi (eg flu epidemics in winter).
And they are collecting both gut and oropharynx microbiome samples at four time points over a year - a first. As well as blood at two time points
2. The breadth of techniques to go find out what's really going on
It's one thing to look for an association between microbiomes and disease, but more important is too look to see how the microbiome could be causing or contributing to the disease
Microbe Discovery blog said:
to investigate the human
microbiome as it relates to ME/CFS,
to determine how bacteria, fungi, viruses – and the immune response to them – contribute to the disease.
That's why they are looking not just at the microbiome but also the blood proteome (all the proteins in the blood) and metabolome (all the metabolites), as well as immune markers, to try to tease out what's going on/going wrong. As they will have samples at four different points (two for blood), they can also correlate changes in the microbiome with changes elsewhere, which gives them a much better chance of finding causal relationship.
Plus, of course, they are making use of a whole load of leading-edge technologies: not just the proteomics and metabolomics but the sequencing of DNA(RNA) to identify the viruses, bacteria and fungi, and their own
VirCapSeq-VERT virus detection system (hailed by Scientific American as one of the 'world-changing ideas' of 2015. I want these people on our case.
In short: great scientist(s), great study. I know it's not to everyone's taste but I hope many patients will consider donating.